title: mGluR4-containing corticostriatal terminals: synaptic interactions with direct and indirect pathway neurons in mice.
abstract: Glutamatergic afferents from the cerebral cortex are the main excitatory drive of striatal projection neurons. The metabotropic glutamate receptor 4 (mGluR4) presynaptically modulates transmission at corticostriatal synapses, and is considered as a potent drug target for Parkinson's disease and other brain disorders. To better characterize the anatomical substrate that underlies the functional effects of mGluR4 in the striatum, we undertook electron microscopic localization studies of mGluR4 expression in the mouse striatum. Our data demonstrate that more than 80 % mGluR4-immunoreactive structures are accounted for by unmyelinated axons and axon terminals, and that almost 50 % putative glutamatergic terminals (i.e. forming asymmetric synapses) express mGluR4 in the mouse striatum. Using vGluT1 as a presynaptic marker of glutamatergic corticostriatal boutons, our findings indicate: (1) all striatal mGluR4-positive terminals co-express vGluT1 immunoreactivity, (2) 44.3 % total striatal glutamatergic terminals co-express vGluT1 and mGluR4, and (3) mGluR4 is expressed in 73.4 % of total striatal vGluT1-positive terminals. To determine if mGluR4 terminals target preferentially direct vs. indirect pathway neurons, mGluR4 immunostaining was combined with D1 receptor immunoreactivity. These data showed that around 30 % mGluR4-immunoreactive glutamatergic terminals target D1 receptor-positive spines (i.e. direct pathway neurons), while almost 70 % formed synapses with D1 receptor-negative spines (i.e. putative indirect pathway neurons). Thus, these immuno-electron microscopic studies suggest that pre-synaptic mGluR4 in striatal glutamatergic terminals is expressed almost exclusively in cortical boutons to subserve regulatory influences upon a large contingent of corticostriatal terminals that preferentially target putative "indirect" pathway striatal projection neurons in mice. These observations provide a rationale for the use of mGluR4 allosteric potentiator as a potential therapy in Parkinson's disease.
authors.affiliation: Yerkes National Primate Research Center, Department of Neurology, UDALL Center of Excellence for Parkinson's Disease, Emory University, 954, Gatewood RD NE, Atlanta, GA, 30329, USA.|Department of Medical Neurobiology (Physiology), The Hebrew University-Hadassa Medical School, P.O. Box 12272, Jerusalem, 91120, Israel.
authors.forename: Liliya
authors.initials: L
authors.lastname: Iskhakova
authors.affiliation: Yerkes National Primate Research Center, Department of Neurology, UDALL Center of Excellence for Parkinson's Disease, Emory University, 954, Gatewood RD NE, Atlanta, GA, 30329, USA. ysmit01@emory.edu.
authors.forename: Yoland
authors.initials: Y
authors.lastname: Smith
mesh_terms: D000818:Animals; D002540:Cerebral Cortex / Q000378:metabolism / Q000648:ultrastructure*; D003342:Corpus Striatum / Q000378:metabolism / Q000648:ultrastructure*; D008297:Male; D051379:Mice; D009434:Neural Pathways / Q000378:metabolism / Q000648:ultrastructure; D017729:Presynaptic Terminals / Q000378:metabolism* / Q000648:ultrastructure*; D018094:Receptors, Metabotropic Glutamate / Q000378:metabolism*; D050598:Vesicular Glutamate Transport Protein 1 / Q000378:metabolism
chemical_list: D018094:Receptors, Metabotropic Glutamate; C493465:Slc17a7 protein, mouse; D050598:Vesicular Glutamate Transport Protein 1; C108823:metabotropic glutamate receptor 4
keywords: Cortex; Dopamine receptor; Glutamate; Metabotropic; Striatum; Vesicular glutamate transporter
references.citation: J Chem Neuroanat. 2006 Dec;32(2-4):101-16
references.pmid: 16914290
references.citation: J Neurosci. 1996 Mar 15;16(6):2044-56
references.pmid: 8604049
references.citation: J Comp Neurol. 2007 Feb 1;500(4):788-806
references.pmid: 17154259
references.citation: Science. 2004 Jun 18;304(5678):1815-9
references.pmid: 15118123
references.citation: Nature. 2010 Jul 29;466(7306):622-6
references.pmid: 20613723
references.citation: Neuropharmacology. 2014 Oct;85:166-77
references.pmid: 24866785
references.citation: Eur J Neurosci. 1993 Oct 1;5(10):1370-7
references.pmid: 8275236
references.citation: Neuropharmacology. 1997 Jun;36(6):845-51
references.pmid: 9225312
references.citation: J Pharmacol Exp Ther. 2012 Oct;343(1):167-77
references.pmid: 22787118
references.citation: Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8861-5
references.pmid: 8415621
references.citation: J Comp Neurol. 1995 Oct 2;360(4):555-70
references.pmid: 8801249
references.citation: Annu Rev Pharmacol Toxicol. 2010;50:295-322
references.pmid: 20055706
references.citation: Mov Disord. 2008;23 Suppl 3:S534-47
references.pmid: 18781680
references.citation: Eur J Neurosci. 2006 Nov;24(10):2813-24
references.pmid: 17156206
references.citation: J Chem Neuroanat. 2001 Jul;22(1-2):13-42
references.pmid: 11470552
references.citation: Trends Neurosci. 1996 Jan;19(1):19-24
references.pmid: 8787136
references.citation: J Neurosci. 2004 Sep 22;24(38):8289-99
references.pmid: 15385612
references.citation: J Comp Neurol. 1998 Apr 13;393(3):332-52
references.pmid: 9548554
references.citation: Neuropharmacology. 2005;49 Suppl 1:26-34
references.pmid: 16023683
references.citation: Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5720-4
references.pmid: 7911245
references.citation: J Comp Neurol. 1998 Jan 5;390(1):5-19
references.pmid: 9456172
references.citation: J Pharmacol Exp Ther. 2012 Feb;340(2):404-21
references.pmid: 22088953
references.citation: Neuropharmacology. 2013 Mar;66:242-52
references.pmid: 22634360
references.citation: J Comp Neurol. 1999 Apr 28;407(1):33-46
references.pmid: 10213186
references.citation: Brain Res Mol Brain Res. 2000 Oct 20;82(1-2):101-6
references.pmid: 11042362
references.citation: Neurosci Lett. 1995 Dec 29;202(1-2):85-8
references.pmid: 8787837
references.citation: Neuroscience. 2002;110(3):403-20
references.pmid: 11906782
references.citation: FASEB J. 2009 Oct;23(10):3619-28
references.pmid: 19525404
references.citation: J Neurosci. 2004 Mar 17;24(11):2633-42
references.pmid: 15028755
references.citation: J Neurosci. 2007 Jun 6;27(23 ):6249-60
references.pmid: 17553998
references.citation: J Comp Neurol. 2006 Nov 10;499(2):231-43
references.pmid: 16977615
references.citation: J Neurosci. 2003 Aug 6;23(18):7218-26
references.pmid: 12904482
references.citation: J Neurosci. 1995 Jul;15(7 Pt 2):5222-37
references.pmid: 7623147
references.citation: J Cell Biol. 1963 Apr;17:208-12
references.pmid: 13986422
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:435-7
references.pmid: 14684481
references.citation: Nat Rev Neurosci. 2005 Oct;6(10):787-98
references.pmid: 16276355
references.citation: CNS Neurol Disord Drug Targets. 2009 Dec;8(6):475-91
references.pmid: 19702565
references.citation: J Neurosci. 1993 Apr;13(4):1372-8
references.pmid: 8463825
references.citation: Front Syst Neurosci. 2014 Jan 30;8:5
references.pmid: 24523677
references.citation: Lancet. 1996 Jul 27;348(9022):219-23
references.pmid: 8684198
references.citation: Prog Neurobiol. 2004 Dec;74(5):271-300
references.pmid: 15582223
references.citation: Neuroscience. 1995 Apr;65(3):709-30
references.pmid: 7609871
references.citation: Cereb Cortex. 2005 Dec;15(12):1928-37
references.pmid: 15758197
references.citation: Nat Neurosci. 2012 Jun;15(6):816-8
references.pmid: 22544310
references.citation: Eur J Neurosci. 2008 Apr;27(7):1647-58
references.pmid: 18380666
references.citation: J Comp Neurol. 1999 Dec 13;415(2):266-84
references.pmid: 10545164
references.citation: J Neurosci. 1996 Aug 1;16(15):4749-56
references.pmid: 8764662
references.citation: Trends Pharmacol Sci. 2001 Mar;22(3):114-20
references.pmid: 11239574
references.citation: Eur J Neurosci. 1998 Dec;10(12):3629-41
references.pmid: 9875342
references.citation: J Comp Neurol. 2007 Feb 10;500(5):908-22
references.pmid: 17177262
references.citation: Neuroscience. 1995 Nov;69(1):167-76
references.pmid: 8637615
references.citation: J Neurosci. 1997 Oct 1;17(19):7503-22
references.pmid: 9295396
references.citation: Mol Pharmacol. 1997 Jan;51(1):119-25
references.pmid: 9016353
references.citation: Annu Rev Pharmacol Toxicol. 1997;37:205-37
references.pmid: 9131252
references.citation: J Neurosci. 2007 Jun 20;27(25):6701-11
references.pmid: 17581957
references.citation: J Neurosci. 2013 Nov 20;33(47):18531-9
references.pmid: 24259575
references.citation: Neuropharmacology. 2013 Mar;66:158-69
references.pmid: 22491024
references.citation: J Neurosci. 2005 Nov 9;25(45):10520-36
references.pmid: 16280590
references.citation: Prog Mol Biol Transl Sci. 2013;115:61-121
references.pmid: 23415092
references.citation: J Neurochem. 2009 May;109(4):1096-105
references.pmid: 19519781